- 1. – Novi oralni antikoagulansi
- 2. – Predstavljanje LABNOAC HRZZ projekta
- 3. – Diplomski rad – Verifikacija metoda za određivanje koncentracije novih oralnih antikoagulansa – dabigatrana, rivaroksabana i apiksabana
- 4. – FG 09-2018 – Pregledni rad Direktni oralni antikoagulacijski lijekovi
- 5. – Posterski rad Relationship between dabigratan concentrations in plasma and results of routine coagulation assays PT, APTT, TT and fibrinogen
- 6. – Određivanje-koncentracije-DOAC-lijekova-rezultati-i-iskustva-HRZZ-IP
- 7. – Sandra Margetić pozvano predavanje DLTH 2019 New oral anticoagulants and the laboratory DLTH
- 8. – Posterski rad DLTH 2019
- 9. – Rektorova nagrada Sveučilišta u Zagrebu – DOAC stop tableta i medicinski aktivni ugljen u uklanjanju interferencije u određivanju pretrage lupus antikoagulans (LAC) u bolesnika liječenih DOAC lijekovima
- 10. – Posterski rad Rektorova nagrada Sveučilišta u Zagrebu
- 11. – Effect of DOACs on the dRVVT screen and confirm assays folr lupus anticoagulant testing
- 12. – Izvorni znanstveni rad_Chromogenic anti-FXa assay calibrated with LMWH in patients treated with rivaroxaban and apixaban possibilities and limitations
- 13. – Izvorni znanstveni rad Analytical verification and comparison of chromogenic assays for dabigatran, rivaroxaban and apixaban determination on BCSXP and STA Compact Max analyzers
- 14. – Posterski rad: Inter-individual variability of peak and trough plasma concentrations of dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation
- 15. – Utjecaj novih oralnih antikoagulacijskih lijekova na probirne pretrage hemostaze, Farmaceutsko-biokemijski fakultet, Sveučilište u Zagrebu, diplomski rad, prosinac 2020.
- 16. – ISTH2019: Comparison of Peak and trough,Concentrations of Dabigatran, Rivaroxaban and Apixaban with the Published Expected Values in Patients with Non Valvular Atrial Fibrillation
- 17. – ISTH2019: Activated Charcoal Is an Effective in vitro Removal Agent of Dabigatran and Rivaroxaban in Plasma of Patients Who Need Lupus Anticoagulant Testing
- 18. – ISTH 2020: Presentation of Three Patients Treated with Dabigatran that Strongly Con_rm the Importance of Quantitative Measurement of Dabigatran Concentration in Selected Clinical Situations: Case Reports.
- 19. – ISTH2020: Does Normal Diluted Russell Viper Venom Time Test Result Can Exclude Concentrations of Direct Oral Anticoagulants below 30 ng/mL?
- 20. – ISTH2020: Effect of Activated Charcoal in Removing Interference in Thrombophilia Assays: Resistance to Activated Protein C, Activity of Coagulation Factor VIII and Antithrombin Activity
- 21. ISTH2020: Comparison of Two Quantitative Methods for Determination of Dabigatran Concentration: Diluted Thrombin Time Test and Innovance Dabigatran Test in Real Life Patients Treated with Dabigatran
- 22. ISTH2020: Is Low Molecular Weight Heparin-Calibrated Chromogenic Anti-Xa Assay Suitable for Assessing Anticoagulant E_ect of Apixaban in Adolescents?
- 23. – GTH 2021: Relationship between DOAC Dipstick test results and quantitative plasma and urine concentrations of DOACs in real-life patient settings – study protocol and case reports
- 24. – ISTH2021: Activated charcoal can be used as an effective in vitro removal agent of direct oral anticoagulants dabigatran, rivaroxaban and apixaban in plasma of patients with protein S activity testing.
- 25. – ISTH2021: Comparison of D-dimer values at peak and trough concentrations of direct oral anticoagulants: result of D-dimer testing is not affected by plasma drug concentration.
- 26. – ISTH 2021: Comparison of Peak Plasma Concentrations of Apixaban in Adolescent and Adult Patients.
- 27. – ISTH2021: Comparison of Visual Interpretation of the DOAC Dipstick Test with a Reader System for Rapid and Accurate Detection of Direct Oral Anticoagulants in Neurology and Cardiology – Interim Data from a Prospective Consecutive Comparative Study.
- 28. – ISTH2021: Presentation of the Patient with Low Peak Dabigatran Levels in Plasma Suggests the Importance of Quantitative Measurement of DOAC Drugs in Clinical Decision Making and Treatment.
- 29. Izvorni znanstveni rad: DOAC Dipstick testing can reliably exclude the presence of clinically relevant DOAC concentrations in circulation
- 30. GTH2022: Comparison of the sensitivity and specificity of rivaroxaban, apixaban and dabigatran concentrations measured in urine samples by the DOAC Dipstick with the cut-off plasma concentration of 30ng/mL – nagrada za najbolji posterski rad na kongresu
- 31. ISTH2022 FVIII and D-dimer values at trough and peak concentrations of direct oral anticoagulants: important considerations for using these tests in assissting clinical decision for risk stratification scheme/.Accessed July 27, 2022.
- 32. Exclusion of relevant concentrations of direct oral anticoagulants in blood by DOAC Dipstick – proposal of a diagnostic algorithm for improvement of clinical decision-making in emergencies/.Accessed July 28, 2022.
- 33. Results of the thrombin time test obtained with two different commercial reagents in real life patients treated with dabigatran/. Accessed July 28, 2022.
- 34. Pregledni rad (Review) Direct oral anticoagulants (DOACs): from the laboratory point of view. Acta Pharm 2022;72.
- 35. Priručnik: Laboratorijska dijagnostika direktnih oralnih antikoagulansa (DOAK)
